Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 1.00 |
| ▸ | SLC16A3 | O15427 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SLC16A1 | P53985 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL28529867 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26826 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26825 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL5530234 | 0.95 | ALDH1A1 (0.90) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL5330094 | 0.93 | KDM4E (0.87) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL5330088 | 0.93 | KDM4E (0.87) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| SCHEMBL4600832 | 0.92 | EGFR (0.85) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| SCHEMBL10413058 | 0.92 | EGFR (0.85) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| SCHEMBL4600830 | 0.92 | EGFR (0.85) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL28674225 | 0.92 | ALDH1A1 (0.84) | KDM4EALDH1A1CISD1SLC16A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019078145-A1 | MATERIAL FOR PREPARING MASS SPECTROMETRY SAMPLE | JSR株式会社 | 2019-04-25 | — | — | WO | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| EP-2797886-A2 | PAIN RELIEF COMPOUNDS | Ecole Nationale Superieure de Chimie de Clermont Ferrand (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| WO-2013098416-A2 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2013-07-04 | — | — | WO | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| US-7276381-B2 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | BIO-RAD LABORATORIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276381-B2 | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes | BIO-RAD LABORATORIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | KDM4E 3722/4885ALDH1A1 2410/4885CISD1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.